Patrick C Gedeon, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Bispecific | 7 | 2020 | 203 | 1.440 |
Why?
|
| Immunotherapy | 8 | 2020 | 4752 | 0.850 |
Why?
|
| Glioma | 8 | 2020 | 3493 | 0.790 |
Why?
|
| Molecular Dynamics Simulation | 4 | 2015 | 431 | 0.690 |
Why?
|
| Neurotransmitter Transport Proteins | 1 | 2015 | 3 | 0.490 |
Why?
|
| Glioblastoma | 4 | 2020 | 3459 | 0.480 |
Why?
|
| Amino Acid Transport Systems, Neutral | 2 | 2016 | 42 | 0.470 |
Why?
|
| Lipid Bilayers | 2 | 2015 | 376 | 0.390 |
Why?
|
| Single-Chain Antibodies | 3 | 2020 | 114 | 0.330 |
Why?
|
| Protein Conformation | 4 | 2016 | 3946 | 0.320 |
Why?
|
| Standard of Care | 1 | 2013 | 567 | 0.310 |
Why?
|
| Brain Neoplasms | 7 | 2020 | 9071 | 0.310 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2010 | 412 | 0.290 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 1106 | 0.280 |
Why?
|
| Lymphocyte Activation | 3 | 2018 | 5501 | 0.280 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 1801 | 0.260 |
Why?
|
| Antibodies | 1 | 2014 | 2417 | 0.260 |
Why?
|
| Plasma Membrane Neurotransmitter Transport Proteins | 2 | 2014 | 23 | 0.220 |
Why?
|
| Leucine | 3 | 2014 | 546 | 0.200 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7851 | 0.150 |
Why?
|
| T-Lymphocytes | 4 | 2020 | 10261 | 0.140 |
Why?
|
| Principal Component Analysis | 3 | 2015 | 951 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2822 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 3608 | 0.120 |
Why?
|
| Phosphatidylethanolamines | 1 | 2015 | 128 | 0.120 |
Why?
|
| Antibody Specificity | 2 | 2013 | 1061 | 0.110 |
Why?
|
| Perforin | 1 | 2013 | 166 | 0.110 |
Why?
|
| Thermodynamics | 1 | 2015 | 580 | 0.100 |
Why?
|
| Complementarity Determining Regions | 1 | 2013 | 154 | 0.100 |
Why?
|
| Animals | 11 | 2020 | 168759 | 0.100 |
Why?
|
| Granzymes | 1 | 2013 | 278 | 0.100 |
Why?
|
| Models, Molecular | 3 | 2016 | 5379 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2018 | 1510 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 13648 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2014 | 547 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2013 | 1347 | 0.080 |
Why?
|
| Body Weight | 1 | 2020 | 4622 | 0.080 |
Why?
|
| Ion Channels | 1 | 2014 | 1045 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 6493 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2352 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3564 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 17075 | 0.070 |
Why?
|
| Mice | 6 | 2020 | 81818 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2017 | 2747 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2010 | 1752 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2010 | 3051 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 2570 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2018 | 3111 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 9249 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 3837 | 0.050 |
Why?
|
| Dopamine | 1 | 2010 | 1582 | 0.050 |
Why?
|
| Surface Plasmon Resonance | 2 | 2013 | 268 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8611 | 0.050 |
Why?
|
| Humans | 14 | 2020 | 765956 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 18294 | 0.040 |
Why?
|
| Software | 1 | 2015 | 4462 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2020 | 116 | 0.040 |
Why?
|
| Sodium | 2 | 2016 | 1591 | 0.040 |
Why?
|
| Protein Binding | 1 | 2010 | 9296 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 20125 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2017 | 192 | 0.030 |
Why?
|
| Ions | 1 | 2016 | 254 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 827 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 1333 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2020 | 6255 | 0.030 |
Why?
|
| Female | 4 | 2020 | 396101 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 751 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2017 | 65189 | 0.030 |
Why?
|
| Chromatography | 1 | 2012 | 187 | 0.030 |
Why?
|
| Ion Transport | 1 | 2014 | 322 | 0.030 |
Why?
|
| Markov Chains | 1 | 2016 | 968 | 0.030 |
Why?
|
| Male | 3 | 2020 | 363691 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2013 | 251 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2013 | 5881 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2013 | 457 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 6113 | 0.020 |
Why?
|
| Chimera | 1 | 2013 | 455 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2018 | 1896 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 2013 | 508 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 13400 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 898 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 1724 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 17594 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2013 | 1679 | 0.020 |
Why?
|
| Neoplasms | 1 | 2018 | 22340 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2013 | 550 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 1837 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2013 | 2171 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2017 | 2446 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 2630 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10729 | 0.020 |
Why?
|
| Bacteria | 1 | 2016 | 2209 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2020 | 10429 | 0.010 |
Why?
|
| Apoptosis | 1 | 2020 | 9514 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 4642 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2012 | 4214 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 23600 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 171114 | 0.000 |
Why?
|
| Middle Aged | 1 | 2017 | 223004 | 0.000 |
Why?
|
| Adult | 1 | 2017 | 223038 | 0.000 |
Why?
|